微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 7.68% | 123.91% | 262.26% | 35/159 | 1.2% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | 2.12% | 5.47% | 85.96% | 79/159 | 0.26% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | 1.14% | -5% | -45.19% | 76/159 | -0.37% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | 2.08% | -37.35% | -39.36% | 87/159 | -9.52% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | 3.43% | -54.93% | 70.65% | 80/159 | 4.23% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 2.01% | -0.5% | 67.5% | 83/159 | 2.66% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 1.2% | 13.21% | -63.86% | 86/159 | 2.32% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 3.32% | 18.15% | -56.37% | 77/159 | -1.03% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 7.61% | 201.98% | 276.73% | 44/159 | 2.34% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 2.02% | 25.47% | 90.57% | 83/159 | 1.46% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 1.06% | 11.58% | -62.28% | 88/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 2.81% | 4.85% | 11.51% | 88/159 | 0.67% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 2.52% | 12% | 56.52% | 89/159 | 2.8% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 1.61% | 19.26% | 69.47% | 94/159 | 2.16% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 0.95% | 14.46% | -64.55% | 93/159 | 1.57% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 2.68% | 4366.67% | 19.11% | 93/159 | 0.75% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 2.25% | 26.4% | 66.67% | 103/159 | 4.43% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 1.35% | 7.14% | 62.65% | 105/159 | 2.94% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 0.83% | 7.79% | 1283.33% | 99/159 | 2.49% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 0.06% | -98.45% | -96.63% | 111/159 | 3.58% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 1.78% | -39.04% | 41.27% | 93/159 | 3.03% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 1.26% | -32.98% | 63.64% | 96/159 | 4.19% | 河化股份 | 45.32% | 行业排名> |
| 2020-03-31 | 0.77% | -20.62% | -80.1% | 73/159 | 2.19% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 3.87% | -25.43% | 32.53% | 96/159 | 2.53% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 2.92% | -13.35% | 55.32% | 85/159 | 7.48% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 1.88% | -14.93% | 93.81% | 88/159 | 4.96% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 0.97% | -26.52% | -81.31% | 85/159 | 2.41% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 5.19% | 47.03% | 54.01% | 85/159 | 6.99% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 3.37% | 2.43% | 52.49% | 82/159 | 7.18% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 2.21% | -14.67% | 67.42% | 80/159 | 4.6% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 1.32% | -1.49% | -62.61% | 71/159 | 2.54% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 3.53% | -7.59% | 7.29% | 95/159 | 9.61% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 3.29% | 24.15% | 27.03% | 75/159 | 8.29% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 2.59% | 14.6% | 93.28% | 74/159 | 5.58% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 1.34% | -6.29% | -64.92% | 55/159 | 2.09% | 河化股份 | 54.24% | 行业排名> |
| 2016-12-31 | 3.82% | -0.52% | 44.15% | 86/159 | 6.19% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 2.65% | -34.57% | 17.26% | 69/159 | 5.61% | 南新制药 | 81.7% | 行业排名> |
| 2016-06-30 | 2.26% | -36.87% | 58.04% | 65/159 | 3.48% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 1.43% | -10.63% | -62.76% | 51/159 | 2.65% | 贝达药业 | 16.78% | 行业排名> |
| 2015-12-31 | 3.84% | 25.49% | -5.19% | 77/159 | 11.27% | 河化股份 | 19.29% | 行业排名> |
| 2015-09-30 | 4.05% | 10.35% | 13.13% | 52/159 | 7.22% | 一品红 | 58.17% | 行业排名> |
| 2015-06-30 | 3.58% | 12.23% | 123.75% | 49/159 | 4.87% | 华东医药 | 36.97% | 行业排名> |
| 2015-03-31 | 1.6% | -27.6% | -47.71% | 45/159 | 2.41% | 华东医药 | 26.63% | 行业排名> |